Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 183

1.

Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.

Lai MT, Munshi V, Lu M, Feng M, Hrin-Solt R, McKenna PM, Hazuda DJ, Miller MD.

Viruses. 2016 Sep 23;8(10). pii: E263. doi: 10.3390/v8100263.

2.

Latency reversal and viral clearance to cure HIV-1.

Margolis DM, Garcia JV, Hazuda DJ, Haynes BF.

Science. 2016 Jul 22;353(6297):aaf6517. doi: 10.1126/science.aaf6517. Review.

PMID:
27463679
3.

Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening.

Barnard R, Chopra A, James I, Blinco J, Watson MW, Jabara CB, Hazuda D, Lemon SM, Mallal S, Gaudieri S.

Antivir Ther. 2016 May 24. doi: 10.3851/IMP3056. [Epub ahead of print]

PMID:
27219495
4.

In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.

Tsai P, Wu G, Baker CE, Thayer WO, Spagnuolo RA, Sanchez R, Barrett S, Howell B, Margolis D, Hazuda DJ, Archin NM, Garcia JV.

Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7.

5.

A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.

Kovarova M, Swanson MD, Sanchez RI, Baker CE, Steve J, Spagnuolo RA, Howell BJ, Hazuda DJ, Garcia JV.

J Antimicrob Chemother. 2016 Jun;71(6):1586-96. doi: 10.1093/jac/dkw042. Epub 2016 Mar 21.

PMID:
27002074
6.

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.

Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, Chase R, Liu R, Black T, Hazuda D, Howe AY, Asante-Appiah E.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2954-64. doi: 10.1128/AAC.00051-16. Print 2016 May.

PMID:
26926625
7.

Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.

Feng M, Sachs NA, Xu M, Grobler J, Blair W, Hazuda DJ, Miller MD, Lai MT.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2241-7. doi: 10.1128/AAC.02650-15. Print 2016 Apr.

8.

Correction to Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.

Raheem IT, Walji AM, Klein D, Sanders JM, Powell DA, Abeywickrema P, Barbe G, Bennet A, Childers K, Christensen M, Clas SD, Dubost D, Embrey M, Grobler J, Hafey MJ, Hartingh TJ, Hazuda DJ, Kuethe JT, McCabe Dunn J, Miller MD, Moore KP, Nolting A, Pajkovic N, Patel S, Peng Z, Rada V, Rearden P, Schreier JD, Sisko J, Steele TG, Truchon JF, Wai J, Xu M, Coleman PJ.

J Med Chem. 2016 Jan 14;59(1):486. doi: 10.1021/acs.jmedchem.5b01957. Epub 2015 Dec 28. No abstract available.

PMID:
26709958
9.

A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals.

Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, Richman DD, O'Doherty U, Palmer S, Hecht FM, Hoh R, Barnard RJ, Miller MD, Hazuda DJ, Deeks SG, Sékaly RP, Chomont N.

EBioMedicine. 2015 Jun 27;2(8):874-83. doi: 10.1016/j.ebiom.2015.06.019. eCollection 2015 Aug.

10.

Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.

Raheem IT, Walji AM, Klein D, Sanders JM, Powell DA, Abeywickrema P, Barbe G, Bennet A, Childers K, Christensen M, Clas SD, Dubost D, Embrey M, Grobler J, Hafey MJ, Hartingh TJ, Hazuda DJ, Kuethe JT, McCabe Dunn J, Miller MD, Moore KP, Nolting A, Pajkovic N, Patel S, Peng Z, Rada V, Rearden P, Schreier JD, Sisko J, Steele TG, Truchon JF, Wai J, Xu M, Coleman PJ.

J Med Chem. 2015 Oct 22;58(20):8154-65. doi: 10.1021/acs.jmedchem.5b01037. Epub 2015 Oct 8. Erratum in: J Med Chem. 2016 Jan 14;59(1):486. Childers, Karla [added]; Christensen, Melodie [added]; Kuethe, Jeffrey T. [added]; McCabe Dunn, Jamie [added]; Nolting, Andrew [added]; Peng, Zuihui [corrected].

PMID:
26397965
11.

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.

Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sékaly RP, Lewin SR.

PLoS Pathog. 2014 Nov 13;10(10):e1004473. doi: 10.1371/journal.ppat.1004473. eCollection 2014 Oct.

12.

In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.

Feng M, Wang D, Grobler JA, Hazuda DJ, Miller MD, Lai MT.

Antimicrob Agents Chemother. 2015 Jan;59(1):590-8. doi: 10.1128/AAC.04201-14. Epub 2014 Nov 10.

13.

Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase.

Bernatchez JA, Paul R, Tchesnokov EP, Ngure M, Beilhartz GL, Berghuis AM, Lavoie R, Li L, Auger A, Melnyk RA, Grobler JA, Miller MD, Hazuda DJ, Hecht SM, Götte M.

J Biol Chem. 2015 Jan 16;290(3):1474-84. doi: 10.1074/jbc.M114.614305. Epub 2014 Oct 29.

14.

Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.

Del Prete GQ, Shoemaker R, Oswald K, Lara A, Trubey CM, Fast R, Schneider DK, Kiser R, Coalter V, Wiles A, Wiles R, Freemire B, Keele BF, Estes JD, Quiñones OA, Smedley J, Macallister R, Sanchez RI, Wai JS, Tan CM, Alvord WG, Hazuda DJ, Piatak M Jr, Lifson JD.

Antimicrob Agents Chemother. 2014 Nov;58(11):6790-806. doi: 10.1128/AAC.03746-14. Epub 2014 Sep 2.

15.

Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences.

Grobler JA, Hazuda DJ.

Curr Opin Virol. 2014 Oct;8:98-103. doi: 10.1016/j.coviro.2014.07.006. Epub 2014 Aug 14. Review.

PMID:
25128610
16.

Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques.

Ling B, Piatak M Jr, Rogers L, Johnson AM, Russell-Lodrigue K, Hazuda DJ, Lifson JD, Veazey RS.

PLoS One. 2014 Jul 17;9(7):e102795. doi: 10.1371/journal.pone.0102795. eCollection 2014.

17.

Exploring possibilities.

Hazuda D, Miller M, Berry J.

Posit Aware. 2014 Jan-Feb;26(1):42-5. No abstract available.

PMID:
24847579
18.

Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors.

Dobard C, Sharma S, Parikh UM, West R, Taylor A, Martin A, Pau CP, Hanson DL, Lipscomb J, Smith J, Novembre F, Hazuda D, Garcia-Lerma JG, Heneine W.

Sci Transl Med. 2014 Mar 12;6(227):227ra35. doi: 10.1126/scitranslmed.3007701.

19.

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, Kearney MF, Anderson EM, Coffin JM, Strain MC, Richman DD, Robertson KR, Kashuba AD, Bosch RJ, Hazuda DJ, Kuruc JD, Eron JJ, Margolis DM.

J Infect Dis. 2014 Sep 1;210(5):728-35. doi: 10.1093/infdis/jiu155. Epub 2014 Mar 11.

20.

In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Lai MT, Feng M, Falgueyret JP, Tawa P, Witmer M, DiStefano D, Li Y, Burch J, Sachs N, Lu M, Cauchon E, Campeau LC, Grobler J, Yan Y, Ducharme Y, Côté B, Asante-Appiah E, Hazuda DJ, Miller MD.

Antimicrob Agents Chemother. 2014;58(3):1652-63. doi: 10.1128/AAC.02403-13. Epub 2013 Dec 30.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk